Caladrius Biosciences Inc (CLBS)

NASDAQ
1.2400
+0.0200(+1.64%)
After Hours
1.2400
0.0000(0.00%)
- Real-time Data
  • Volume:
    140,749
  • Bid/Ask:
    1.2400/1.2500
  • Day's Range:
    1.2200 - 1.2400

CLBS Overview

Prev. Close
1.22
Day's Range
1.22-1.24
Revenue
-
Open
1.23
52 wk Range
1.15-4.89
EPS
-0.85
Volume
140,749
Market Cap
73.8M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
356,998
P/E Ratio
-
Beta
1.05
1-Year Change
-38.61%
Shares Outstanding
59,517,458
Next Earnings Date
Nov 11, 2021
What is your sentiment on Caladrius Biosciences Inc?
or
Market is currently closed. Voting is open during market hours.

Caladrius Biosciences Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyNeutralSellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyBuyStrong SellStrong Sell

Caladrius Biosciences Inc Company Profile

Caladrius Biosciences Inc Company Profile

Employees
24

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FREEDOM) study in the United States for the treatment of coronary microvascular dysfunction (CMD); HONEDRA (CLBS12), recipient of SAKIGAKE designation in Japan for the treatment of critical limb ischemia (CLI); CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis chronic kidney disease (CKD), and OLOGO (CLBS14), which reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, the product received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA).

Read More
  • it needs more recognition.
    0
    • sell at 3 y'all
      1
      • Very good !!!!
        0
        • great potential. buy
          0
          • Time to buy
            0
            • I Knew this one has potential 🚀 to the Moon
              0
              • any more comments
                0
                • Is this going to go up ? Beyond 4$ anytime ?
                  0
                  • They have good news. Should be over 4
                    0
                  • Monte Carlo I see it as pump n dump :/
                    0
                • in @ 3,5 USD. Tried to catch up the train
                  0
                  • 💸
                    0
                    • Could break new sparking a positive rally at any time. In fact I am expecting it based on what the CEO said in his last press release video.
                      1
                      • I agree. This is one to watch.
                        0
                    • Major move after hours! Buy!
                      0
                      • Premarket looks great today!
                        0
                        • I think something will happend!’
                          0
                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.